Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

0.3384 +0.0079 (+2.39%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Ovid Therapeutics: Q1 Earnings Insights
Via Benzinga
Looking Into Ovid Therapeutics's Return On Capital Employed
Via Benzinga
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
3 Very Promising Penny Stocks That Are Flying Under the Radar
Although the very concept of penny stocks to buy screams risk, these ideas just might be intriguing enough for speculators. 
Via InvestorPlace
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Added to Russell 3000® Index
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
From Ovid Therapeutics Inc.
Via GlobeNewswire
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech
One executive called this the most "damaging" decision in five decades. 
Via Investor's Business Daily
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension
Via Benzinga
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
From Ovid Therapeutics Inc.
Via GlobeNewswire
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options 
From Ovid Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.